Analysis of the expression changes of IL-17+ γδ T cells and Treg cells in bone marrow mesenchymal stem cells targeted therapy for allergic rhinitis

B. ZOU, R.-X. ZHUANG, X.-Y. SUN, J. LIANG

Department of Otorhinolaryngology, Children's Hospital of Chongqing Medical University, Chongqing, China; National Clinical Research Center for Child Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Pediatrics, Chongqing, China

Abstract. – **OBJECTIVE:** Bone marrow mesenchymal stem cells (BMSCs) have immunomodulatory and therapeutic effects on immune system diseases. This study intends to assess the regulatory effect of BMSC targeted therapy on the IL-17+ γδ T cells and Treg cells in allergic rhinitis (AR).

MATERIALS AND METHODS: BALB/c mice were sensitized by ovalbumin (OVA), while BMSCs were injected intravenously before sensitization and followed by an analysis of nasal symptoms, inflammation, cytokines, and immunoglobulins. BMSCs were co-cultured with peripheral blood mononuclear cells for 3 days to test Foxp3+ expression, IL-17+ γδ T and Foxp3+Treg cell ratio, and cytokines secretion.

RESULTS: After intranasal administration of BMSCs, nasal symptoms and inflammatory infiltration in mice were significantly alleviated, accompanied by reduced OVA-specific IgE in serum. BMSCs significantly inhibited the activity of T lymphocytes, increased TGF-β1 level, decreased IL-17A level, promoted Treg proliferation, and suppressed the proliferation of IL-17+ γδ T cells.

CONCLUSIONS: BMSC targeted therapy can be used to treat AR by regulating Treg cells to correct IL-17+γδ T cell immune imbalance and is expected to be an effective treatment method for AR.

Key Words:
   IL-17+ γδ T cells, Treg cells, BMSC, AR.

Introduction

At present, the AR treatment mainly includes avoiding contact with susceptible allergens, anti-inflammatory, antihistamine, and other symptomatic treatments, but the effect is unideal[1-5]. Allergen-specific immunotherapy (AIT) is the only etiological treatment for allergic diseases approved by the WHO[6-11]. Drug treatment can reduce allergic symptoms. Allergen immunotherapy can be used in patients resistant to conventional therapies[12-14]. The desensitizers currently used in clinics are mainly derived from allergens' crude extracts, featured as complex components, poor stability, difficulty in standardization, and serious side effects. Immunotherapy includes regular injections of allergen vaccines to trigger allergen tolerance[15-17]. However, it is limited by the types of allergens. Moreover, long-term treatment cycles usually lead to poor clinical compliance[18]. Therefore, it is particularly important to develop new, safe, and effective methods to prevent AR.

The immune regulation ability of BMSCs is shown in several allergic disease models, which might be used to treat immune diseases[19-23]. BMSCs are considered a new method for the treatment of AR as they can reduce eosinophils infiltration and control CD4+ T cell response[24-27]. Since BMSCs are easily obtained[28-30], we intend to assess the regulatory effect of BMSC targeted therapy on the expression of IL-17+ γδ T cells and Treg cells in AR.

Materials and Methods

AR Mouse Animal Model

AR mouse model has been established *via* intraperitoneal injection of 25 µg OVA as described

Corresponding Author: Jia Liang, MD; e-mail: zoubin@hospital.cqmu.edu.cn

previously[16]. After 28 days, the mice were sacrificed by cervical dislocation under anesthesia.

Mice were used for all experiments, and all procedures were approved by the Animal Ethics Committee of Children's Hospital of the Chongqing Medical University.

BMSC Treatment of AR Mouse Model

BMSCs were purchased from Lonza Company (CH-4002 Basel, Switzerland) as T25 cell culture flasks (second generation) and cultured in complete DMEM/F12. BMSCs were administrated into mice on the 18th, 19th, and 20th days. The sensitized mice were assigned into PBS group and sensitized group which were injected with PBS after the OVA challenge; and BMSC group, which was injected with BMSC on the basis of the OVA challenge.

Symptoms of Nasal Allergy and Inflammatory Cell Infiltration

On the 27th day after treatment of each group, within 10 minutes after last administration of nasal egg, frequency of sneezing and nasal friction were recorded. Inflammatory cell infiltration was detected by nasal irrigation fluid.

OVA-Specific IgE Measurement

24 hours after the last OVA challenge, blood was taken from the mouse eyeballs. The egg specific IgE level was measured by ELISA kit.

MTT Analysis of Cell Proliferation

In the quantitative proliferation experiment, after stimulating proliferation, the number of cells was plated in a conventional medium, and the digested cells were respectively inoculated in the corresponding culture equipment according to the designed density to analyze the effect of cell proliferation. The cells were washed, attached to a 24-well plate, and then incubated in a medium containing 5% CO_2. The cells in each group were treated for 48h after treatment according to the various conditions. The cell proliferation evaluation was analyzed on the 6th day using an automatic cell counter, and the absorbance was analyzed by a spectrometer with a wavelength of 495 nm.

Real-Time PCR

RNA was isolated and cDNA was then synthesized, followed by qPCR using Universal SYBR qPCR Green Mix (Bio-Rad, 1000 Alfred Nobel Drive, Hercules, CA, USA). The relative expression was evaluated by drawing a standard curve and standardizing the difference in Ct. The primer sequences were listed in Table I.

ELISA Analysis

The above-mentioned culture supernatant was collected to measure the secretion of BDNF by ELISA. The results were expressed in pg/mL.

Flow Cytometric Analysis

The data were analyzed by FlowJo software (version 7.6).

Statistical Analysis

Statistics are carried out in accordance with the statistical methodology and analyzed with statistical software. SPSS 18.0 (SPSS Inc., Chicago, IL, USA) software was applied for data analysis. Measurement data was presented as mean ± standard deviation and compared by t test or one-way ANOVA. $p<0.05$ was depicted as significant difference.

Results

Analysis of Nasal Symptoms Caused by BMSC Targeted Therapy of AR

The frequency of sneezing and nasal friction in each group of mice was recorded separately so as to analyze the changes of BMSC targeted treatment of AR on nasal symptoms. The frequency of sneezing and friction in mice with AR increased ($p<0.05$), while BMSC targeted therapy for AR significantly reduced the frequency of sneezing and nasal friction in mice ($p<0.05$) (Figure 1).

Table I. Primer sequence.

| Gene	Forward 5′-3′	Reverse 5′-3′
GAPDH	AGTATGTTGTCACCGCTGG	TAACCTGTCTATACGGAGGGT
Foxp3	GCGGGATGAGGGGTCA	GACACGTTCTGTCGAGGT

Figure 1. Analysis of changes in nasal symptoms of BMSC targeted therapy for AR. Compared with the control group, the frequency of sneezing and nasal friction in mice with AR increased (*$p<0.05$); BMSC targeted therapy for AR can significantly reduce the frequency of sneezing and nasal friction in mice, compared with the AR group ($^\#p<0.05$).

Analysis of BMSC Targeted Treatment on Inflammatory Infiltrating Cells

Eosinophilic inflammatory infiltrating cells in nasal cavity of mice with increased ($p<0.05$), while BMSC targeted therapy for AR significantly reduced inflammatory infiltrating cells in mice ($p<0.05$) (Figure 2).


Figure 2. Analysis of BMSC targeted treatment of inflammatory infiltrating cells in AR. Compared with the control group, inflammatory infiltrating cells in the nasal cavity washing fluid of mice with AR increased, and the difference was statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly reduce the decrease in inflammatory infiltrating cells in mice, compared with the AR group ($^\#p<0.05$).


Figure 3. Analysis of serum IgE levels in BMSC targeted therapy for AR. Compared with the control group, the serum IgE level of mice with AR increased, and the difference was statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly reduce the serum IgE level, which is comparable to AR group comparison ($^\#p<0.05$).

Analysis of Serum IgE Levels in BMSC Targeted Therapy for AR

The level of IgE in the serum of mice with AR increased ($p<0.05$), and BMSC targeted therapy for AR significantly reduced the level of IgE in the serum ($p<0.05$) (Figure 3).

The Effect of BMSC Targeted Therapy on the Proliferation of T Lymphocytes

PHA stimulation significantly promoted T lymphocyte proliferation ($p<0.05$), while BMSC targeted treatment inhibited its promotion of T lymphocyte proliferation ($p<0.05$) (Figure 4).


Figure 4. The effect of BBMSC targeted therapy for AR on the proliferation of T lymphocytes. Compared with the control group, PHA stimulation can significantly promote the proliferation of T lymphocytes, and the difference is statistically significant (*$p<0.05$); BMSC targeting treatment inhibits the promotion of T lymphocyte proliferation under PHA stimulation, and the PHA group comparison ($^\#p<0.05$).

Figure 5. The effect of BMSC targeted therapy on serum TGF-β1 levels in AR. The TGF-β1 concentration unit is pg/ml; compared with the control group, the TGF-β1 level in the serum of AR mice is reduced, and the difference is statistically significant (*$p<0.05$); BMSC targeted therapy for AR can be significant promote the level of TGF-β1 in serum, compared with AR group, (#$p<0.05$).

The Effect of BMSC Targeted Therapy on Serum TGF-β1 Level in AR

TGF-β1 level in mice with AR decreased ($p<0.05$), while BMSC targeted therapy for AR significantly increased the level of TGF-β1 ($p<0.05$) (Figure 5).

The Effect of BMSC Targeted Therapy on Serum IL-17A Level in AR

The level of interleukin-17A in the serum of mice with AR increased ($p<0.05$), and BMSC targeted therapy for AR significantly reduced the level of interleukin-17A ($p<0.05$) (Figure 6).

The Effect of BMSC Targeted Therapy on Serum IL-10 level in AR

The level of interleukin-10 in the serum of mice with AR upregulated ($p<0.05$), and BMSC targeted therapy for AR significantly declined the level of interleukin-10 ($p<0.05$) (Figure 7).

Effect of BMSC Targeted Therapy on IL-17+ γδ T Cells

IL-17+ γδ T cells in AR increased ($p<0.05$), while BMSC targeted therapy for AR significantly inhibited IL-17+ γδ T cells ($p<0.05$) (Figure 8).

Effects of BMSC Targeted Therapy on Treg Cells

Treg cells in AR decreased ($p<0.05$), while BMSC targeted therapy for AR significantly promoted Treg cells ($p<0.05$) (Figure 9).

Effect of BMSC Targeted Therapy on Foxp3 Expression in Mice with AR

Foxp3 expression in the nasal tissues of mice with AR decreased ($p<0.05$), while BMSC targeted therapy for AR significantly promoted Foxp3 in the nasal tissues ($p<0.05$) (Figure 10).

Discussion

AR is a common and frequently occurring disease in clinical practice[23]. At present, symptomatic treatment based on histamine and other anti-inflammatory drugs cannot achieve satisfactory results. We transplanted BMSCs into


Figure 6. The effect of BMSC targeted therapy on serum IL-17A levels in AR. Compared with the control group, the IL-17A level in the serum of mice with AR increased, and the difference was statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly reduce the level of IL-17A in the serum. Comparison of AR group (#$p<0.05$).

Figure 7. The effect of BMSC targeted therapy on serum IL-10 levels in AR. Compared with the control group, the IL-10 level in the serum of mice with AR increased, and the difference was statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly reduce the level of IL-10 in the serum. Comparison of AR group (#$p<0.05$).

Figure 8. The effect of BMSC targeted therapy on the level of IL-17+ γδ T in AR. A flow cytometry analysis of the effects of BMSC targeting treatment on IL-17+ γδ T cells in AR mice; statistical analysis of the effects of BBMSC targeting treatment on IL-17+ γδ T cells in AR mice, compared with the control group, IL-17+ γδ T cells in AR mice increased, and the difference was statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly inhibit IL-17+ γδ T cells, compared with the AR group (#$p<0.05$).

AR mouse models to assess BMSCs' effect on IL-17+ γδ T cells and Treg cells after AR treatment. AR is featured as a decrease in the ratio of helper T cell subsets[31-33]. In this study, we observed that BMSCs promote the proliferation of regulatory T cells, inhibit the proliferation of IL-17+ γδ T cells, and reduce nasal-related inflammation symptoms. BMSCs can significantly increase the level of TGF-β1, reduce the level of IL-17A, and reduce IgE production in mice. Foxp3 level increased after BMSC injection, reflecting the immunosuppressive effect from another side.

Figure 9. The effect of BMSC targeted therapy on Treg levels in AR. A flow cytometry analysis of the effect of BMSC targeted therapy on Treg cells in mice with AR; statistical analysis of the impact of BBMSC targeted therapy on Treg cells in mice with AR. Compared with the control group, Treg cells in mice with AR Increase, the difference is statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly inhibit Treg cells, compared with the AR group (#$p<0.05$).

Some studies have confirmed that BMSCs can increase the Th1/Th2 ratio, which is consistent with studies on adipose mesenchymal stem cells[34]. Th17 cells were involved in the infiltration of neutrophils and macrophages in AR[35-37]. Studies have shown that BMSC has a significant inhibitory effect on Th17 cells *in vitro*. Our results show that the IL-17A secretion level in the serum of AR mice after BMSC transplantation is


Figure 10. The effect of BMSC targeted therapy on Foxp3 expression in AR. Compared with the control group, the expression of Foxp3 in mice with AR increased, and the difference was statistically significant (*$p<0.05$); BMSC targeted therapy for AR can significantly inhibit the expression of Foxp3, compared with the AR group (#$p<0.05$).

significantly reduced, indicating that BMSCs can inhibit γδ T cells in AR mice and delay progression. In addition, Treg cells inhibit the inflammatory process[38-41]. Many studies have shown that after using BMSC in asthma models, the number and activity of Treg cells are up-regulated[42-44]. It is well known that BMSCs suppress the immune response by inhibiting the proliferation of T cells[45]. Compared with the OVA group, Foxp3 mRNA level in lymphocytes in BMSC group was significantly increased, which provides evidence for BMSCs to exert anti-inflammatory effects through Foxp3+Treg amplification in the AR mouse model. The soluble factor TGF-β1 is considered to be the main inducer of Treg cell during T cell differentiation[46]. Wang et al[47] have shown that neutralizing TGF-β1 can eliminate the immunosuppressive effect of ASC. This study shows that BMSCs enhance the frequency of CD4+CD25+Foxp3+Treg, suggesting that the change of TGF-β1 may be a potential way for BMSCs to promote Treg expansion.

Conclusions

We showed that BMSC targeted therapy can treat AR by regulating Treg cells to correct the immune imbalance of IL-17+ γδ T cells, and it is expected to become a cell therapy program for the treatment of related allergic diseases.

Conflict of Interest
The Authors declare that they have no conflict of interests.

References

1) Kim WG, Kang GD, Kim HI, Han MJ, Kim DH. Bifidobacterium longum IM55 and Lactobacillus plantarum IM76 alleviate allergic rhinitis in mice by restoring Th2/Treg imbalance and gut microbiota disturbance. Benef Microbes 2019; 10: 55-67.

2) Jiao WE, Wei JF, Kong YG, Xu Y, Tao ZZ, Chen SM. Notch signaling promotes development of allergic rhinitis by suppressing Foxp3 expression and Treg cell differentiation. Int Arch Allergy Immunol 2019; 178: 33-44.

3) Hu W, Ma L, Yang G, Zeng X, Liu J, Cheng B, Hu T, Zhao H, Liu Z. Der p2A20 DNA vaccine attenuates allergic inflammation in mice with allergic rhinitis. Mol Med Rep 2019; 20: 4925-4932.

4) Liu W, Ouyang H, Zeng Q, Luo R, Lu G. Decreased Treg-derived miR-181a and miR-155 correlated with reduced number and function of Treg cells in allergic rhinitis children. Eur Arch Otorhinolaryngol 2019; 276: 1089-1094.

5) Wang YX, Gu ZW, Cao ZW, Hao LY. Nonylphenol can aggravate allergic rhinitis in a murine model by regulating important Th cell subtypes and their associated cytokines. Int Immunopharmacol 2019; 70: 260-267.

6) Wang J, Shen Y, Li C, Liu C, Wang ZH, Li YS, Ke X, Hu GH. IL-37 attenuates allergic process via STAT6/STAT3 pathways in murine allergic rhinitis. Int Immunopharmacol 2019; 69: 27-33.

7) Zeng Q, Liu W, Luo R, Lu G. MicroRNA-181a and microRNA-155 are involved in the regulation of the differentiation and function of regulatory T cells in allergic rhinitis children. Pediatr Allergy Immunol 2019; 30: 434-442.

8) Chen H, Lou H, Wang Y, Cao F, Zhang L, Wang C. Comparison of the efficacy and mechanisms of intranasal budesonide, montelukast, and their combination in treatment of patients with seasonal allergic rhinitis. Int Forum Allergy Rhinol 2018; 8: 1242-1252.

9) Chen R, Lee WY, Zhang XH, Zhang JT, Lin S, Xu LL, Huang B, Yang FY, Liu HL, Wang B, Tsang LL, Willaime-Morawek S, Li G, Chan HC, Jiang X. Epigenetic modification of the CCL5/CCR1/ERK axis enhances glioma targeting in dedifferentiation-reprogrammed BMSCs. Stem Cell Rep 2017; 8: 743-757.

10) Vilaca-Faria H, Salgado AJ, Teixeira FG. Mesenchymal stem cells-derived exosomes: a new possible therapeutic strategy for Parkinson's disease? Cells 2019; 8: 118.

11) Gu ZW, Wang YX, Cao ZW. Neutralization of interleukin-17 suppresses allergic rhinitis symptoms by downregulating Th2 and Th17 responses and upregulating the Treg response. Oncotarget 2017; 8: 22361-22369.

12) Ni K, Zhao L, Wu J, Chen W, HongyaYang, Li X. Th17/Treg balance in children with obstructive sleep apnea syndrome and the relationship with allergic rhinitis. Int J Pediatr Otorhinolaryngol 2015; 79: 1448-54.

13) Ariaee N, Ghorbani J, Panahi M, Mohamadi M, Asili J, Ranjbar A, Farid Hoseini R, Jabbari F. Oral administration of Zataria multiflora extract decreases IL-17 expression in perennial allergic rhinitis. Rep Biochem Mol Biol 2018; 6: 203-207.

14) Piao CH, Kim TG, Bui TT, Song CH, Shin DU, Eom JE, Lee SY, Shin HS, Chai OH. Ethanol extract of Dryopteris crassirhizoma alleviates allergic inflammation via inhibition of Th2 response and mast cell activation in a murine model of allergic rhinitis. J Ethnopharmacol 2019; 232: 21-29.

15) Li L, Guan K, Zhou Y, Wu J, Wang Y, Wang W. Prostaglandin E2 signal inhibits T regulatory cell differentiation during allergic rhinitis inflammation through EP4 receptor. World Allergy Organ J 2019; 12: 100090.

2863

16) Zhang Y, Zhen H, Yao W, Bian F, Mao X, Yang X, Jin S. Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg and Th17 cells. Int J Immunopathol Pharmacol 2013; 26: 107-115.

17) Melchiotti R, Puan KJ, Andiappan AK, Poh TY, Starke M, Zhuang L, Petsch K, Lai TS, Chew FT, Larbi A, Wang de Y, Poidinger M, Rotzschke O. Genetic analysis of an allergic rhinitis cohort reveals an intercellular epistasis between FAM134B and CD39. BMC Med Genet 2014; 15: 73.

18) Li J, Lin X, Liu X, Ma Z, Li Y. Baicalin regulates Treg/Th17 cell imbalance by inhibiting autophagy in allergic rhinitis. Mol Immunol 2020; 125: 162-171.

19) Bui TT, Piao CH, Hyeon E, Fan Y, Choi DW, Jung SY, Jang BH, Shin HS, Song CH, Chai OH. Preventive effect of bupleurum chinense on nasal inflammation via suppressing T helper type 2, eosinophil and mast cell activation. Am J Chin Med 2019; 47: 405-421.

20) Zheng R, Wu X, Huang X, Chen Y, Yang Q, Li Y, Zhang G. Gene expression pattern of Treg and TCR Vgamma subfamily T cells before and after specific immunotherapy in allergic rhinitis. J Transl Med 2014; 12: 24.

21) Xin Y, Cai H, Lu T, Zhang Y, Yang Y, Cui Y. MiR-20b inhibits T cell proliferation and activation via NFAT signaling pathway in thymoma-associated myasthenia gravis. Biomed Res Int 2016; 2016: 9595718.

22) Lee HE, Kim YH, Kim SM, Shin HY. Clinical significance of repetitive compound muscle action potentials in patients with Myasthenia gravis: a predictor for cholinergic side effects of acetylcholinesterase inhibitors. J Clin Neurol 2016; 12: 482-488.

23) Tasaniyananda N, Chaisri U, Tungtrongchitr A, Chaicumpa W, Sookrung N. Mouse model of cat allergic rhinitis and intranasal liposome-adjuvanted refined Fel d 1 vaccine. PLoS One 2016; 11: e0150463.

24) Gung Y, Zhang H, Li S, Wang Y. Sternotomy versus video-assisted thoracoscopic surgery for thymectomy of myasthenia gravis patients: A meta-analysis. Asian J Endosc Surg 2016; 9: 285-294.

25) Li Q, Liu P, Xuan X, Zhang J, Zhang Y, Zhu Z, Gao F, Zhang Q, Du Y. CCR9 and CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. Muscle Nerve 2017; 55: 84-90.

26) Zhang H, Geng Y, Zheng Y, Wang Y. A case of anterior mediastinitis and bilateral multiple lung abscesses occurring after trans-subxiphoid video-assisted thoracoscopic extended thymectomy for thymoma with myasthenia gravis. J Thorac Dis 2016; 8: E970-E973.

27) Nikolic AV, Bojic SD, Rakocevic Stojanovic VM, Basta IZ, Lavrnic DV. Electrophysiological findings in patients with low density lipoprotein receptor related protein 4 positive myasthenia gravis. Eur J Neurol 2016; 23: 1635-1641.

28) Vargas-Rojas MI, Solleiro-Villavicencio H, Soto-Vega E. Th1, Th2, Th17 and Treg levels in umbilical cord blood in preeclampsia. J Matern Fetal Neonatal Med 2016; 29: 1642-1645.

29) Tian T, Yu S, Liu L, Xue F, Yuan C, Wang M, Ji C, Ma D. The Profile of T Helper Subsets in Bone marrow microenvironment is distinct for different stages of acute myeloid leukemia patients and chemotherapy partly ameliorates these variations. PLoS One 2015; 10: e0131761.

30) Kornete M, Mason ES, Girouard J, Lafferty EI, Qureshi S, Piccirillo CA. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and home to beta-Islets During Pre-Diabetes in BDC2.5 NOD mice. PLoS One 2015; 10: e0126311.

31) Anand G, Vasanthakumar R, Mohan V, Babu S, Aravindhan V. Increased IL-12 and decreased IL-33 serum levels are associated with increased Th1 and suppressed Th2 cytokine profile in patients with diabetic nephropathy (CURES-134). Int J Clin Exp Pathol 2014; 7: 8008-8015.

32) Dalakas MC. Future perspectives in target-specific immunotherapies of myasthenia gravis. Ther Adv Neurol Disord 2015; 8: 316-27.

33) Luo J, Lindstrom J. AChR-specific immunosuppressive therapy of myasthenia gravis. Biochem Pharmacol 2015; 97: 609-619.

34) Yu Y, Cao F, Ran Q, Sun X. Regulatory T cells exhibit neuroprotective effect in a mouse model of traumatic brain injury. Mol Med Rep 2016; 14: 5556-5566.

35) Uzawa A, Kanai T, Kawaguchi N, Oda F, Himuro K, Kuwabara S. Changes in inflammatory cytokine networks in myasthenia gravis. Sci Rep 2016; 6: 25886.

36) Li H, Wang CC, Zhang M, Li XL, Zhang P, Yue LT, Miao S, Wang S, Liu Y, Li YB, Duan RS. Statin-modified dendritic cells regulate humoral immunity in experimental autoimmune myasthenia gravis. Mol Cell Neurosci 2015; 68: 284-92.

37) Fan X, Lin C, Han J, Jiang X, Zhu J, Jin T. Follicular helper CD4+ T cells in human neuroautoimmune diseases and their animal models. Mediators Inflamm 2015; 2015: 638968.

38) Yilmaz V, Oflazer P, Aysal F, Durmus H, Poulas K, Yentur SP, Gulsen-Parman Y, Tzartos S, Marx A, Tuzun E, Deymeer F, Saruhan-Direskeneli G. Differential cytokine changes in patients with myasthenia gravis with antibodies against AChR and MuSK. PLoS One 2015; 10: e0123546.

39) Fu Y, Kong Y, Li J, Wang Y, Li M, Wang Y, Wang Y, Ren F, Ni J, Li Y, Chang Z. Mesenchymal stem cells combined with traditional Chinese medicine (qi-fang-bi-min-tang) alleviates rodent allergic rhinitis. J Cell Biochem 2020; 121: 1541-1551.

40) Tanaka Y, Fukumoto S, Sugawara S. Mechanisms underlying the induction of regulatory T cells by sublingual immunotherapy. J Oral Biosci 2019; 61: 73-77.

41) Botturi K, Lacoeuille Y, Cavailles A, Vervloet D, Magnan A. Differences in allergen-induced T

cell activation between allergic asthma and rhinitis: Role of CD28, ICOS and CTLA-4. Respir Res 2011; 12: 25.

42) Datta A, Moitra S, Das PK, Mondal S, Omar Faruk SM, Hazra I, Tripathi SK, Chaudhuri S. Allergen immunotherapy modulates sensitivity of Treg cells to apoptosis in a rat model of allergic asthma. Immunotherapy 2017; 9: 1239-1251.

43) Li J, Wang B, Luo Y, Bian Y, Wang R. Effect of artemisinin and neurectomy of pterygoid canal in ovalbumin-induced allergic rhinitis mouse model. Allergy Asthma Clin Immunol 2018; 14: 22.

44) Fan XL, Zeng QX, Li X, Li CL, Xu ZB, Deng XQ, Shi J, Chen D, Zheng SG, Fu QL. Induced pluripotent stem cell-derived mesenchymal stem cells activate quiescent T cells and elevate regulatory T cell response via NF-kappaB in allergic rhinitis patients. Stem cell Res Ther 2018; 9: 170.

45) Sahin E, Bafaqeeh SA, Guven SG, Cetinkaya EA, Muluk NB, Coskun ZO, Lopatin A, Kar M, Pinarbasli MO, Cingi C. Mechanism of action of allergen immunotherapy. Am J Rhinol Allergy 2016; 30: 1-3.

46) Shiue HS, Lee YS, Tsai CN, Hsueh YM, Sheu JR, Chang HH. Gene expression profile of patients with phadiatop-positive and -negative allergic rhinitis treated with acupuncture. J Altern Complement Med 2010; 16: 59-68.

47) Wang N, Schoos AM, Larsen JM, Brix S, Thysen AH, Rasmussen MA, Stokholm J, Bonnelykke K, Bisgaard H, Chawes BL. Reduced IL-2 response from peripheral blood mononuclear cells exposed to bacteria at 6months of age is associated with elevated total-IgE and allergic rhinitis during the first 7years of life. EBioMedicine 2019; 43: 587-593.